Zhang Linlin, Lyer Arun K, Yang Xiaoqian, Kobayashi Eisuke, Guo Yuqi, Mankin Henry, Hornicek Francis J, Amiji Mansoor M, Duan Zhenfeng
Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA ; Department of Pathology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, Massachusetts, USA ; Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, USA.
Int J Nanomedicine. 2015 Apr 15;10:2913-24. doi: 10.2147/IJN.S79143. eCollection 2015.
Our prior screening of microRNAs (miRs) identified that miR-199a-3p expression is reduced in osteosarcoma cells, one of the most common types of bone tumor. miR-199a-3p exhibited functions of tumor cell growth inhibition, suggesting the potential application of miR-199a-3p as an anticancer agent. In the study reported here, we designed and developed a lipid-modified dextran-based polymeric nanoparticle platform for encapsulation of miRs, and determined the efficiency and efficacy of delivering miR-199a-3p into osteosarcoma cells. In addition, another potent miR, let-7a, which also displayed tumor suppressive ability, was selected as a candidate miR for evaluation. Fluorescence microscopy studies and real-time polymerase chain reaction results showed that dextran nanoparticles could deliver both miR-199a-3p and let-7a into osteosarcoma cell lines (KHOS and U-2OS) successfully. Western blotting analysis and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays demonstrated that dextran nanoparticles loaded with miRs could efficiently downregulate the expression of target proteins and effectively inhibit the growth and proliferation of osteosarcoma cells. These results demonstrate that a lipid-modified dextran-based polymeric nanoparticle platform may be an effective nonviral carrier for potential miR-based anticancer therapeutics.
我们之前对微小RNA(miR)的筛选发现,在骨肉瘤细胞(最常见的骨肿瘤类型之一)中,miR-199a-3p的表达降低。miR-199a-3p具有抑制肿瘤细胞生长的功能,这表明miR-199a-3p作为抗癌剂具有潜在的应用价值。在本文报道的研究中,我们设计并开发了一种基于脂质修饰葡聚糖的聚合物纳米颗粒平台用于包裹miR,并确定了将miR-199a-3p递送至骨肉瘤细胞中的效率和效果。此外,另一种同样具有肿瘤抑制能力的强效miR,即let-7a,被选作评估的候选miR。荧光显微镜研究和实时聚合酶链反应结果表明,葡聚糖纳米颗粒能够成功地将miR-199a-3p和let-7a递送至骨肉瘤细胞系(KHOS和U-2OS)。蛋白质印迹分析和3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐(MTT)测定表明,装载miR的葡聚糖纳米颗粒能够有效下调靶蛋白的表达,并有效抑制骨肉瘤细胞的生长和增殖。这些结果表明,基于脂质修饰葡聚糖的聚合物纳米颗粒平台可能是一种有效的非病毒载体,用于潜在的基于miR的抗癌治疗。